Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
GenSpera, Inc. (“GenSpera” or “the Company”) is a development-stage biotechnology company focused on the discovery and development of prodrug cancer therapies. A prodrug is an inactive precursor of a drug that is converted into its active form at a targeted site. The Company has developed a novel approach to chemotherapy using a prodrug to deliver a potent, cell-killing agent to tumor sites while avoiding toxicity in healthy, non-cancerous cells. GenSpera’s prodrugs target cancer cells in one of two ways: (1) by targeting tumor-associated blood vessels; or (2) by targeting tumors directly.
The Company’s lead prodrug candidate, G-202, is designed to attack existing tumor vasculature, potentially debilitating the tumor’s nutrient supply and causing cancer regression without affecting normal tissues within the body. In preclinical evaluation, G-202 demonstrated anti-tumor effects on the growth of breast, renal, bladder, and prostate cancers. Due to G-202′s specific mechanism of action as well as its solid preclinical breast cancer data, GenSpera has selected breast cancer as the initial clinical focus, and intends to submit an Investigational New Drug (IND) application for G-202 during the second quarter 2009. Further, to prepare for clinical trials, the Company has formulated a Phase I clinical plan for G-202 together with investigators at
The Company’s technology can also be used to attack cancer cells directly by targeting the prodrug to enzymes believed to be found solely at a tumor location. G-115, GenSpera’s primary candidate using this approach, targets prostate-specific antigen (PSA), a protein produced by the cells of the prostate gland that is used by physicians as a “tumor marker” to detect the presence of prostate cancer. The Company is also working to identify additional candidates in this program.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates’ unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company’s product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company’s technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company’s periodic reports, including forms filed with the SEC.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
SOURCE Crystal Research Associates, LLC